(Global Health Strategies) For the first time, global funding for neglected disease R&D grew for three consecutive years, reaching a record high of more than US$4.05 billion in 2018. Increases from the public and private sectors drove a 7.9% rise in total global funding compared to the previous year. Investment has translated into a robust innovation pipeline with more than 500 candidates in development, though not all diseases are receiving the investments in R&D they need.

Original source: https://www.eurekalert.org/pub_releases/2020-01/ghs-ffn012820.php